Marshall Wace, LLP Novartis Ag Transaction History

Marshall Wace, LLP

$77.3 Billion
Q3 2024

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$95.27 - $108.47 $28.7 Million - $32.7 Million	-301,075 Reduced 69.64%	131,247 $12.7 Million
Q4 2023 Feb 14, 2024	SELL	$92.27 - $101.54 $57.6 Million - $63.4 Million	-624,720 Reduced 59.1%	432,322 $43.7 Million
Q3 2023 Nov 14, 2023	BUY	$94.73 - $105.13 $1.4 Million - $1.55 Million	14,730 Added 1.41%	1,057,042 $108 Million
Q2 2023 Aug 14, 2023	SELL	$92.52 - $104.91 $26.3 Million - $29.8 Million	-283,844 Reduced 21.4%	1,042,312 $105 Million
Q1 2023 May 15, 2023	BUY	$80.03 - $92.81 $41 Million - $47.5 Million	511,869 Added 62.86%	1,326,156 $122 Million
Q4 2022 Feb 14, 2023	SELL	$75.55 - $92.52 $4.42 Million - $5.41 Million	-58,454 Reduced 6.7%	814,287 $73.9 Million
Q3 2022 Nov 14, 2022	SELL	$74.61 - $87.26 $3.35 Million - $3.92 Million	-44,958 Reduced 4.9%	872,741 $66.3 Million
Q2 2022 Aug 15, 2022	BUY	$80.52 - $93.75 $19.2 Million - $22.4 Million	239,038 Added 35.22%	917,699 $77.6 Million
Q1 2022 May 16, 2022	BUY	$80.11 - $90.62 $41.9 Million - $47.4 Million	522,888 Added 335.67%	678,661 $59.6 Million
Q4 2021 Feb 14, 2022	BUY	$79.7 - $88.13 $12.4 Million - $13.7 Million	155,773 New	155,773 $13.6 Million
Q2 2018 Aug 14, 2018	SELL	$64.91 - $73.36 $1.5 Million - $1.7 Million	-23,166 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$70.39 - $84.15 $41,107 - $49,143	-584 Reduced 2.46%	23,166 $1.87 Million
Q4 2017 Feb 14, 2018	BUY	$72.33 - $77.64 $722,721 - $775,778	9,992 Added 72.63%	23,750 $1.99 Million
Q3 2017 Nov 13, 2017	BUY	$74.14 - $77.27 $1.02 Million - $1.06 Million	13,758	13,758 $1.18 Million

Others Institutions Holding NVS

# of Institutions

1,437

Shares Held

133M

Call Options Held

1.12M

Put Options Held

1.83M

View Full List

About NOVARTIS AG

Ticker NVS
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,151,000,064
Market Cap $223B
Description
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatol...

More about NVS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Account